MedTrace Logo

Prevalence of IL28B Polymorphism in Hepatitis C Patients

NCT03415009 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 39

Last updated 2018-01-30

No results posted yet for this study

Summary

Response to peginterferon and ribavirin treatment in hepatitis C (HCV) depends on viral and host factors. Single nucleotide polypmorphisms (SNP) near to IL28B gene (especially at rs12979860 and rs8099917) are strongly associated with the response to treatment in HCV genotype 1 infection, less so in HCV genotype 2/3 infection. CC genotype in rs12979860 and TT genotype at rs8099917 are associated with good treatment outcome. Asian populations have high prevalence of CC genotype in other studies, which can explain relatively good response to peginterferon/ ribavirin in genotype 1 infection in Asians compared with Caucasians.

Conditions

  • Hepatitis C

Sponsors & Collaborators

  • Changi General Hospital

    lead OTHER

Principal Investigators

  • Poh Yen Loh · Changi General Hospital

Eligibility

Min Age
21 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2016-06-30
Completion
2016-12-31

Countries

  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03415009 on ClinicalTrials.gov